## Note
nid: 1496029410295
model: AnKingOverhaul
tags: #AK_Original_Decks::Step_1::Zanki_Pharmacology, #AK_Step1_v11::!FLAG_THESE_CARDS::!DELETE, #AK_Step1_v11::#B&B::11_Hematology::04_Cancer_Drugs::06_Other_Cancer_Drugs, #AK_Step1_v11::#FirstAid::10_Hematology_Oncology::05_Pharm::20_Erlotinib, #AK_Step1_v11::#OME_banner, #AK_Step1_v11::#Pixorize::02_Biochem::22_Onc_Drugs::21_Erlotinib, #AK_Step1_v11::#Pixorize::03_Pharm::11_Oncology::Erlotinib, #AK_Step1_v11::#SketchyPharm::08_Antineoplastics::03_Kinase_Inhibitors_&_Monoclonal_Antibodies::01_Imatinib,_erlotinib,_sorafenib,_sunitinib,_vemurafenib::zanki_extra, #AK_Step1_v11::^Other::^EXPN, #AK_Step1_v11::^Other::^HighYield::4-LowerYield
markdown: false

### Text
<div>
  Patients taking <b>Erlotinib</b> can get a(n)
  {{c1::<b>papulopustular acneiform</b>}} <b>rash</b>
</div>

### Extra
<i>Dermatological side effects are common with EGFR inhibitors
since there are high concentrations of EGFR in the skin</i>
<div>
  <i><img src="paste-81866371629057.jpg"></i>
</div>

### Lecture Notes


### Missed Questions


### Pathoma


### Boards and Beyond


### First Aid
<img src="paste-37280316129283%20(1).jpg"><img src=
"paste-323204878958595.jpg"><img src=
"paste-326542068547587.jpg"><img src="paste-330222855520259.jpg">
<!--EndFragment-->

### Sketchy
<img src="paste-386186279387137.jpg" class="resizer"><img src=
"paste-6ef6236c9786ccaaf69cacfab716239d037e3c2e.png" class=
"resizer">

### Pixorize


### Physeo


### OME
<div class="ome-widget">
  <a href="https://onlinemeded.org?ref=anki"><img src=
  "_OME_AnkiFlashcards_General_7.png"></a>
</div>

### Additional Resources


### One by one

